Wells Fargo & Company Rezolute, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RZLT
# of Institutions
62Shares Held
38.5MCall Options Held
1.6KPut Options Held
24.6K-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$50 Million0.13% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.8MShares$12.4 Million1.99% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.58MShares$11.4 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$8.56 Million0.0% of portfolio
-
Blackstone Inc New York, NY1.74MShares$7.73 Million0.04% of portfolio
About Rezolute, Inc.
- Ticker RZLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,600
- Market Cap $172M
- Description
- Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...